DEA Revokes De Novo Services' Drug Handling License Over Decade of Sloppiness
Published Date: 4/23/2025
Notice
Summary
De Novo Services, LLC lost its DEA registration because it didn’t keep good control over controlled substances and broke recordkeeping rules from 2013 to 2023. Since they didn’t ask for a hearing, the DEA decided to revoke their registration, meaning they can’t legally handle these drugs anymore. This affects De Novo directly and signals a strict stance on drug safety and record rules.
Analyzed Economic Effects
3 provisions identified: 1 benefits, 2 costs, 0 mixed.
DEA Registration Revoked for De Novo
De Novo Services, LLC (DEA Certificate No. RD0424515) had its DEA registration revoked for failures to control and account for controlled substances between 2013 and 2023. Because De Novo did not request a hearing, the DEA entered a final order revoking the registration effective May 23, 2025.
Pending Renewal and New Applications Denied
The DEA denied any pending applications by De Novo Services, LLC to renew or modify its registration and denied any other pending application by De Novo for additional registration in Utah. Those denials accompany the revocation order and are part of the final agency action.
Final Adjudication Creates Public Record and Deterrence
The DEA adjudicated this matter to finality to create an official public record to educate current and prospective registrants about their responsibilities and to inform stakeholders of the Agency's enforcement priorities. The decision states that specific and general deterrence weighed in favor of revocation.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526, Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128, Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2025-05007, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
Starting December 31, 2025, veterans can get buprenorphine treatment and follow-up care through telemedicine, making it easier to access help for opioid use disorder without leaving home. This change affects veterans using VA health services and aims to improve treatment access while the government reviews feedback and policies. No new costs are mentioned, but the delay gives agencies time to ensure the rules work well.
2025-02793, Expansion of Buprenorphine Treatment via Telemedicine Encounter and Continuity of Care via Telemedicine for Veterans Affairs Patients
The government is giving veterans easier access to buprenorphine treatment through telemedicine, letting them get care remotely. This change affects veterans using VA health services and aims to make treatment smoother and more convenient. The new rules were supposed to start February 18, 2025, but now they’ll kick in on March 21, 2025, while the government gathers public feedback.
2026-20749, Vladimir Romaniv, P.A.; Decision and Order
The DEA has officially suspended and is moving to revoke Vladimir Romaniv, P.A.'s registration because he gave multiple prescriptions without properly checking on a patient who was in jail. This affects Romaniv’s ability to prescribe controlled substances and signals serious legal trouble starting from late 2025. If you’re connected to his practice or rely on his prescriptions, expect changes and tighter controls soon.
2026-20750, L Krenk DBA Maui Clinic Pharmacy; Decision and Order
The DEA has officially revoked L Krenk DBA Maui Clinic Pharmacy’s registration because they broke important rules about where and how they handled controlled substances. This affects the pharmacy in Kahului, Hawaii, which can no longer legally dispense these drugs. The decision is final, and the pharmacy missed its chance to defend itself, so the revocation takes effect immediately, impacting their business and customers.
Previous / Next Documents
Previous: 2025-07025, Extension of Agency Information Collection Activity Under OMB Review: Enhanced Security Procedures at Ronald Reagan Washington National Airport
The TSA is asking to keep collecting info from small plane pilots and armed security officers at Ronald Reagan Washington National Airport. Pilots need to pick a security coordinator and follow special safety rules. This helps keep everyone safe without adding extra costs or delays.
Next: 2025-07029, Draft Aquaculture Opportunity Area Options-Alaska State Waters
NOAA is exploring spots in Alaska’s state waters where fish farms could grow and thrive, aiming to boost local seafood business and jobs. They’ve picked some draft areas and want your thoughts before making final decisions. This is a big step toward smarter, eco-friendly aquaculture, with public input shaping the future and no money changes yet.